The role of lipophilic bile acids in the development of cirrhotic cardiomyopathy.
Marked hemodynamic changes occur in humans and experimental animals with cirrhotic liver disease. In the heart, basal contractility, responsiveness to beta-adrenoceptor activation, and excitation-contraction coupling (ECC) are negatively affected in models of cirrhosis and portal hypertension with portosystemic shunting (PVS), and comprise what has been called cirrhotic cardiomyopathy. These effects are accompanied by elevated circulating levels of bile acids. We investigated whether elevated bile acids act as a myocardial toxicant by exposing cardiac muscle in vitro to bile acids and compared these results with two models of cirrhotic cardiomyopathy with elevated bile acids: CCl4-induced cirrhosis and PVS. Cholic acid, a lipophilic bile acid, produced a decrease in basal cardiac contractility and responsiveness to beta-adrenoceptor activation, both of which appeared to result from altered ECC. beta-Adrenoceptor density and signaling were unaffected. Acutely, ursodeoxycholic acid, a more hydrophilic bile acid, had no effect. Cirrhosis produced a decrease in basal force, depressed beta-adrenoceptor responsiveness, and altered ECC similar to cholic acid. However, cirrhosis also altered beta-adrenoceptor signaling including decreases in cyclic AMP formation, expression of the stimulatory G protein, GS, and beta-adrenoceptor density. Displacement of lipophilic bile acids by chronic administration of ursodeoxycholic acid to rats during the development of cirrhotic cardiomyopathy produced by PVS produced attenuation of the effect on ECC. These results suggest a possible role for lipophilic bile acids in some, but not all of the myocardial consequences of chronic portal vein stenosis and CCl4-induced cirrhosis.
Zavecz
James H
JH
Department of Pharmacology, Toxicology and Neuroscience, Louisiana State University Health Sciences Center, 1501 Kings Highway, P.O. Box 33932, Shreveport, LA 71130-3932, USA. jzavec@lsuhsc.edu
Battarbee
Harold D
HD
D000818:Animals; D001647:Bile Acids and Salts / Q000494:pharmacology / Q000502:physiology*; D009202:Cardiomyopathies / Q000209:etiology* / Q000378:metabolism; D019826:Cholic Acid / Q000494:pharmacology / Q000502:physiology; D056966:Excitation Contraction Coupling / Q000187:drug effects; D008106:Liver Cirrhosis, Experimental / Q000150:complications* / Q000209:etiology / Q000378:metabolism; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D009924:Organ Culture Techniques; D010210:Papillary Muscles / Q000187:drug effects / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011943:Receptors, Adrenergic, beta / Q000378:metabolism; D015398:Signal Transduction; D014580:Ursodeoxycholic Acid / Q000494:pharmacology / Q000502:physiology
D001647:Bile Acids and Salts; D011943:Receptors, Adrenergic, beta; D014580:Ursodeoxycholic Acid; D019826:Cholic Acid